Search for Clinical Trial Results

Sponsored By

Hyper-IgM Immunodeficiency Syndrome, Type 1 - 13 Studies Found

Status Study
Completed Study Name: Study of Immune Responses and Safety of Recombinant Human CD40 Ligand in Patients With X-Linked Hyper-IgM Syndrome
Condition: Immunoproliferative Disorder
Date: 1999-11-03
Interventions:
  • Drug: Bacteriophage
  • Drug: rhuCD40L
Terminated Study Name: Studies of Disorders in Antibody Production and Related Primary Immunodeficiency States
Condition:
  • Hyper-IgM Syndrome
  • Ectodermal Dysplasia

Date: 2005-12-16
Completed Study Name: Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
Condition:
  • Primary Immune Deficiency Disorders
  • Common Variable Immunodeficiency
  • Biological: Gammaplex (5%)
  • Biological: Gam
Completed Study Name: Study of Genetic and Molecular Defects in Primary Immunodeficiency Disorders
Condition:
  • X-Linked Agammaglobulinemia
  • X-Linked Hyper IgM Syndrome
    • Date: 1999-10-18
Completed Study Name: A Study to Find Out How Safe and Effective Gammaplex® is in Young People With Primary Immunodeficiency
Condition:
  • Primary Immune Deficiency Disorders
  • Common Variable Immunodeficiency
  • Immunologic Deficiency Syndromes
  • Chediak-Higashi Syndrome

  • Date: 2000-07-05
    Interventions:
    • Drug: anti-thymocyte globulin
    • Drug: busulf
Recruiting Study Name: Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies
Condition:
  • SCID
  • Omenn's Syndrome
  • Reticular Dysgenesis
  • Date: 2012-07-25
    Interventions:
    • Drug: Alemtuzumab 0.3 mg 0.3 m
Completed Study Name: Safety and Efficacy Study of Flebogamma 5% DIF IGIV in Pediatric Subjects
Condition: Primary Immune Deficiency Disease
Date: 2008-03-05
Interventions: Biological: Flebogamma 5% DIF Intravenous Immune Globulin (Human)
Active, not recruiting Study Name: Reduced Intensity Conditioning for Hemophagocytic Syndromes or Selected Primary Immune Deficiencies (BMT CTN 1204)
Condition:
  • Hemophagocytic Lymphohistiocytosis
  • Chronic Active Epstein-Barr Virus Infection
  • Date: 2013-10-29
    Interventions: Biological: Hematopoietic Stem Cell Transplant NOTE: The -
Completed Study Name: A Clinical Study of Intravenous Immunoglobulin
Condition: Immunologic Deficiency Syndromes
Date: 2007-05-01
Interventions: Drug: Immune Globulin Intravenous (Human) Omr-IgG-am IGIV IGIV infusions of 300-900 mg/kg every 3 or 4 w
Next >>>